TICAR SUMMARY
TICAR®
brand of
sterile ticarcillin disodium
for Intramuscular or Intravenous Administration
Ticar is a semisynthetic injectable penicillin derived from the penicillin nucleus, 6-aminopenicillanic acid.
Ticar is indicated for the treatment of the following infections:
Bacterial septicemia‡
Skin and soft-tissue infections‡
Acute and chronic respiratory tract infections‡§
‡ Caused by susceptible strains of Pseudomonas aeruginosa, Proteus species (both indole-positive and indole-negative) and Escherichia coli.
§ Though clinical improvement has been shown, bacteriological cures cannot be expected in patients with chronic respiratory disease or cystic fibrosis.
Genitourinary tract infections (complicated and uncomplicated) due to susceptible strains of Pseudomonas aeruginosa, Proteus species (both indole-positive and indole-negative), Escherichia coli, Enterobacter and Streptococcus faecalis (enterococcus).
Ticarcillin is also indicated in the treatment of the following infections due to susceptible anaerobic bacteria:
- Bacterial septicemia.
- Lower respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess.
- Intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract).
- Infections of the female pelvis and genital tract, such as endometritis, pelvic inflammatory disease, pelvic abscess and salpingitis.
- Skin and soft-tissue infections.
Although ticarcillin is primarily indicated in gram-negative infections, its in vitro activity against gram-positive organisms should be considered in treating infections caused by both gram-negative and gram-positive organisms (see Microbiology).
Based on the in vitro synergism between ticarcillin and gentamicin sulfate, tobramycin sulfate or amikacin sulfate against certain strains of Pseudomonas aeruginosa, combined therapy has been successful, using full therapeutic dosages. (For additional prescribing information, see the gentamicin sulfate, tobramycin sulfate and amikacin sulfate package inserts.)
NOTE: Culturing and susceptibility testing should be performed initially and during treatment to monitor the effectiveness of therapy and the susceptibility of the bacteria.
|
